Recently, many cardiologists have begun to advocate the use of new diabetes medications, such as glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors [28-30]. This evidence concerns the gene SLC5A2 and diabetes mellitus.